Stocks · News reference

Xenetic Biosciences Announces That Its Collaboration Partner PeriNess Received Israeli Ministry Of Health Approval To Conduct An Exploratory Clinical Study Of Combination Systemic DNase I With Anti-CD19 CAR T Cells In Large B Cell Lymphoma Patients

Jun 4, 2026, 12:51 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 7, 2026, 1:28 PMBenzinga Newsdesk
Xenetic Biosciences Q2 EPS $(0.41) Up From $(0.45) YoY, Sales $660.601K Up From $589.897K YoY
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.41) per share. This is a 8.89 percent increase over losses of $(0.45) per share from the same period last year. The company reported $660.601 thousand
Read original at benzinga
XBIO
SEC EDGARAug 7, 2026, 12:35 PMSEC EDGAR
8-K filing — Xenetic Biosciences, Inc. (XBIO)
Filed: 2026-08-07 AccNo: 0001683168-26-006077 Size: 228 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
XBIO
BenzingaJun 1, 2026, 1:06 PMBenzinga Newsdesk
Xenetic Biosciences Reports ASCO 2026 Data Showing DNase I Boosts CAR-T Expansion And Anti-Tumor Activity In B-Cell Cancer Models
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignanciesData highlight potential of DNase I to improve CAR-T cell
Read original at benzinga
XBIO